Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154


The NF1 somatic mutational landscape in sporadic human cancers.

Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M.

Hum Genomics. 2017 Jun 21;11(1):13. doi: 10.1186/s40246-017-0109-3. Review.


Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.

Wee P, Wang Z.

Cancers (Basel). 2017 May 17;9(5). pii: E52. doi: 10.3390/cancers9050052. Review.


Focus on cutaneous and uveal melanoma specificities.

Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C.

Genes Dev. 2017 Apr 15;31(8):724-743. doi: 10.1101/gad.296962.117. Review.


RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.

Dorard C, Estrada C, Barbotin C, Larcher M, Garancher A, Leloup J, Beermann F, Baccarini M, Pouponnot C, Larue L, Eychène A, Druillennec S.

Nat Commun. 2017 May 12;8:15262. doi: 10.1038/ncomms15262.


Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging.

Mikula H, Stapleton S, Kohler RH, Vinegoni C, Weissleder R.

Theranostics. 2017 Mar 6;7(5):1257-1265. doi: 10.7150/thno.18238. eCollection 2017.


Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells.

Basit F, van Oppen LM, Schöckel L, Bossenbroek HM, van Emst-de Vries SE, Hermeling JC, Grefte S, Kopitz C, Heroult M, Hgm Willems P, Koopman WJ.

Cell Death Dis. 2017 Mar 30;8(3):e2716. doi: 10.1038/cddis.2017.133.


Familial risk for lung cancer.

Kanwal M, Ding XJ, Cao Y.

Oncol Lett. 2017 Feb;13(2):535-542. doi: 10.3892/ol.2016.5518. Epub 2016 Dec 20.


BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors.

Breton Q, Plouhinec H, Prunier-Mirebeau D, Boisselier B, Michalak S, Menei P, Rousseau A.

Brain Behav. 2017 Feb 10;7(3):e00641. doi: 10.1002/brb3.641. eCollection 2017 Mar.


The clinical impact of serrated colorectal polyps.

O'Connell BM, Crockett SD.

Clin Epidemiol. 2017 Feb 22;9:113-125. doi: 10.2147/CLEP.S106257. eCollection 2017. Review.


Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.

de Langen AJ, Smit EF.

Ther Adv Med Oncol. 2017 Jan;9(1):46-58. doi: 10.1177/1758834016670555. Epub 2016 Oct 3. Review.


MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling.

Xu K, Chen G, Li X, Wu X, Chang Z, Xu J, Zhu Y, Yin P, Liang X, Dong L.

Sci Rep. 2017 Feb 8;7:41718. doi: 10.1038/srep41718.


Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation.

Kim BA, Jee HG, Yi JW, Kim SJ, Chai YJ, Choi JY, Lee KE.

Cancer Genomics Proteomics. 2017 Jan 2;14(1):53-67.


Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2 in MDCK Cells Expressing Active Ras or Raf.

Kawabata N, Matsuda M.

PLoS One. 2016 Dec 9;11(12):e0167940. doi: 10.1371/journal.pone.0167940. eCollection 2016.


Lung Cancer Biomarkers.

Villalobos P, Wistuba II.

Hematol Oncol Clin North Am. 2017 Feb;31(1):13-29. doi: 10.1016/j.hoc.2016.08.006. Review.


Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.

Li Y, Cheng HS, Chng WJ, Tergaonkar V.

Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14402-14407. Epub 2016 Nov 23.


The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC.

Li L, Zhao GD, Shi Z, Qi LL, Zhou LY, Fu ZX.

Oncol Lett. 2016 Nov;12(5):3045-3050. Epub 2016 Sep 9.


p15 Expression Differentiates Nevus from Melanoma.

Taylor LA, O'Day C, Dentchev T, Hood K, Chu EY, Ridky TW, Seykora JT.

Am J Pathol. 2016 Dec;186(12):3094-3099. doi: 10.1016/j.ajpath.2016.08.009. Epub 2016 Nov 14.


Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy.

Harris Z, Donovan MG, Branco GM, Limesand KH, Burd R.

Front Nutr. 2016 Oct 31;3:48. eCollection 2016. Review.


A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.

Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, Forouhar F, Modzelewski B, Mitchell CM, Yamashiro DJ, Marks LJ, Glade Bender JL, Kung AL.

Genome Med. 2016 Oct 31;8(1):116. doi: 10.1186/s13073-016-0366-0.


High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer.

Padhan N, Nordling TE, Sundström M, Åkerud P, Birgisson H, Nygren P, Nelander S, Claesson-Welsh L.

BMC Cancer. 2016 Aug 25;16(1):683. doi: 10.1186/s12885-016-2725-z.

Supplemental Content

Support Center